Isoxazoline compounds as inhibitors of tnf release
CA 2185019 C · Owner: Pfizer Limited · Inventors: Cohan, Victoria L.; Kleinman, Edward F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates, to isoxazoline compounds of formula (I) which, are inhibitors of tumor necrosis factor (TNF). The, isoxazoline compounds are useful for inhibiting, TNF in a mammal in need thereof and in the, treatment or alleviation of inflammatory conditions, or disease including but, not limited to rheumatoid arthritis, osteoarthritis, asthma, bronchitis chronic obstructive airways disease, psoriais allergic rhinitis, dermatitis and inflammatory bowel disease sepsis, septic, shock, tuberculosis, graft versus host disease and cachexia associated with AIDS or cancer. This invention also relates to pharmaceutical compositions useful therefor comprising such compounds of formula (I) …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 3, 1995 and granted August 8, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 3, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 3, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.